Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study.
Glucose perturbations
Mannose
Myocardial infarction
Risk marker
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
23 09 2022
23 09 2022
Historique:
received:
20
06
2022
accepted:
13
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Plasma mannose, an emerging novel biomarker of insulin resistance, is associated with both diabetes mellitus and coronary atherosclerosis, but the relationship between mannose concentrations and myocardial infarction (MI) across different glycaemic states remains to be elucidated. The aim of this study was to investigate the independent association between mannose and a first MI in a group of subjects characterized according to their glycaemic state. Fasting plasma mannose concentrations were analysed in 777 patients 6-10 weeks after a first myocardial infarction and in 770 matched controls by means of high-performance liquid chromatography coupled to tandem mass spectrometry. Participants without known diabetes mellitus were categorized by an oral glucose tolerance test (OGTT) as having normal glucose tolerance (NGT, n = 1045), impaired glucose tolerance (IGT, n = 246) or newly detected type 2 diabetes (T2DM, n = 112). The association between mannose and MI was investigated across these glycaemic states by logistic regression. Mannose levels increased across the glycaemic states (p < 0.0001) and were significantly associated with a first MI in the whole study population (odds ratio, OR: 2.2; 95% CI 1.4 to - 3.5). Considering the different subgroups separately, the association persisted only in subjects with NGT (adjusted OR: 2.0; 95% CI 1.2-3.6), but not in subgroups with glucose perturbations (adjusted OR: 1.8, 95% CI 0.8-3.7). Mannose concentrations increased across worsening levels of glucose perturbations but were independently associated with a first MI only in NGT individuals. Thus, mannose might be a novel, independent risk marker for MI, possibly targeted for the early management of previously unidentified patients at high cardiovascular risk.
Sections du résumé
BACKGROUND
Plasma mannose, an emerging novel biomarker of insulin resistance, is associated with both diabetes mellitus and coronary atherosclerosis, but the relationship between mannose concentrations and myocardial infarction (MI) across different glycaemic states remains to be elucidated. The aim of this study was to investigate the independent association between mannose and a first MI in a group of subjects characterized according to their glycaemic state.
METHODS
Fasting plasma mannose concentrations were analysed in 777 patients 6-10 weeks after a first myocardial infarction and in 770 matched controls by means of high-performance liquid chromatography coupled to tandem mass spectrometry. Participants without known diabetes mellitus were categorized by an oral glucose tolerance test (OGTT) as having normal glucose tolerance (NGT, n = 1045), impaired glucose tolerance (IGT, n = 246) or newly detected type 2 diabetes (T2DM, n = 112). The association between mannose and MI was investigated across these glycaemic states by logistic regression.
RESULTS
Mannose levels increased across the glycaemic states (p < 0.0001) and were significantly associated with a first MI in the whole study population (odds ratio, OR: 2.2; 95% CI 1.4 to - 3.5). Considering the different subgroups separately, the association persisted only in subjects with NGT (adjusted OR: 2.0; 95% CI 1.2-3.6), but not in subgroups with glucose perturbations (adjusted OR: 1.8, 95% CI 0.8-3.7).
CONCLUSIONS
Mannose concentrations increased across worsening levels of glucose perturbations but were independently associated with a first MI only in NGT individuals. Thus, mannose might be a novel, independent risk marker for MI, possibly targeted for the early management of previously unidentified patients at high cardiovascular risk.
Identifiants
pubmed: 36151569
doi: 10.1186/s12933-022-01630-5
pii: 10.1186/s12933-022-01630-5
pmc: PMC9508730
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glucose
IY9XDZ35W2
Mannose
PHA4727WTP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
195Informations de copyright
© 2022. The Author(s).
Références
Diabetes Care. 2020 Apr;43(4):726-733
pubmed: 32079627
Stat Med. 2015 Feb 10;34(3):396-405
pubmed: 25318454
Eur Heart J. 2004 Nov;25(21):1880-90
pubmed: 15522466
PLoS One. 2015 Nov 16;10(11):e0142045
pubmed: 26571120
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):25-32
pubmed: 31722562
Diabetes Care. 2013 Feb;36(2):328-35
pubmed: 23002083
Diabetes Care. 2019 Aug;42(8):1504-1511
pubmed: 31182493
Diabetes Care. 2003 Mar;26(3):688-96
pubmed: 12610023
Glob Heart. 2012 Dec;7(4):275-95
pubmed: 25689940
Diabetol Metab Syndr. 2018 Dec 04;10:88
pubmed: 30534205
Cell Metab. 2016 Jul 12;24(1):172-84
pubmed: 27345421
Circulation. 2016 Feb 9;133(6):576-83
pubmed: 26762521
Clin Chim Acta. 1996 Jul 15;251(1):91-103
pubmed: 8814353
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
Lancet. 2002 Jun 22;359(9324):2140-4
pubmed: 12090978
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
Diabetes Care. 1999 Feb;22(2):233-40
pubmed: 10333939
Diabetes Care. 1999 Jun;22(6):920-4
pubmed: 10372242
Diabetes Care. 2017 Sep;40(9):1233-1240
pubmed: 28637653
Eur J Endocrinol. 2022 Jun 27;187(2):279-291
pubmed: 35670619
Metabolism. 2020 Jan;102:153974
pubmed: 31682799
Int J Cardiol. 2022 Jan 1;346:86-92
pubmed: 34800594
Eur Heart J. 2018 Aug 1;39(29):2740-2745
pubmed: 29701834
Cardiovasc Diabetol. 2015 Oct 01;14:133
pubmed: 26427624
Metabolism. 2003 Aug;52(8):1019-27
pubmed: 12898467
Cell Metab. 2017 Aug 1;26(2):281-283
pubmed: 28768165
Clin Chim Acta. 2019 Jun;493:31-35
pubmed: 30802440
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967